Exclusive Summary

• - Large, undertreated global populations in depression/anxiety and PMDD sustain steady SSRI demand; paroxetine CR covers MDD/PD/SAD/PMDD.
• - Enteric-coated sustained-release design improves GI tolerability and adherence; 12.5/25 mg supports low-dose initiation and fine titration, differentiating from IR.
• - Fully genericized with no patent barriers; typical 60–90% price discount versus originator in most markets.
• - US-FDA GMP and US registration provide reusable CTD/BE package, enabling faster multi-country registrations and compliant market entry.
• - Distribution-ready, ideal for partners with psychiatric/gynecology access and reimbursement capabilities to scale quickly.